ST-1898 / SciTech Pharma, AccSalus Biosciences - LARVOL DELTA

Study of ST-1898 in Advanced Renal Cell Carcinoma (clinicaltrials.gov) - P1/2 | N=90 | Active, not recruiting | Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • Thyroid Gland Carcinoma

A Study of ST-1898 for Unresectable or Metastatic Melanoma (clinicaltrials.gov) - P1/2 | N=64 | Recruiting | Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited | Trial completion date: Sep 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

A Study of ST-1898 for Unresectable or Metastatic Melanoma (clinicaltrials.gov) - P1/2 | N=64 | Recruiting | Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited

Metastases • New P1/2 trial • Melanoma • Oncology • Solid Tumor

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited

Metastases • New P2 trial • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Study of ST-1898 in Advanced Renal Cell Carcinoma (clinicaltrials.gov) - P1/2 | N=90 | Recruiting | Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited

Metastases • New P1/2 trial • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor